Literature DB >> 21447352

From snake venom toxins to therapeutics--cardiovascular examples.

Cho Yeow Koh1, R Manjunatha Kini.   

Abstract

Snakes have fascinated the imaginations of people since the dawn of civilization. Their deadly venoms cause significant mortality and morbidity worldwide, and strike fear in most of us. Snake venoms contain a huge variety of molecules affecting vital physiological systems, and scientists are turning some of these life-threatening toxins into a source of life-saving therapeutics. Since the approval of captopril--the first drug based on snake venom protein--more than 30 years ago, snake venom toxins have become a valuable natural pharmacopeia of bioactive molecules that provide lead compounds for the development of new drugs. Many toxins are being explored and developed into drugs for the treatment of conditions such as hypertension, thrombosis and cancer. A number of new drugs are constantly emerging from this pipeline. In this review, we briefly highlight the molecular basis of developing therapeutic agents, such as Captopril, Tirofiban, and Eptifibatide, from snake venom proteins. We also discuss the successes and failures as an update to the advances in the field. Copyright Â
© 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21447352     DOI: 10.1016/j.toxicon.2011.03.017

Source DB:  PubMed          Journal:  Toxicon        ISSN: 0041-0101            Impact factor:   3.033


  48 in total

1.  Chemical punch packed in venoms makes centipedes excellent predators.

Authors:  Shilong Yang; Zhonghua Liu; Yao Xiao; Yuan Li; Mingqiang Rong; Songping Liang; Zhiye Zhang; Haining Yu; Glenn F King; Ren Lai
Journal:  Mol Cell Proteomics       Date:  2012-05-17       Impact factor: 5.911

2.  Current Understanding of the Compensatory Actions of Cardiac Natriuretic Peptides in Cardiac Failure: A Clinical Perspective.

Authors:  Noel S Lee; Lori B Daniels
Journal:  Card Fail Rev       Date:  2016-05

3.  Evaluation of cytotoxic activities of snake venoms toward breast (MCF-7) and skin cancer (A-375) cell lines.

Authors:  Michael J Bradshaw; Anthony J Saviola; Elizabeth Fesler; Stephen P Mackessy
Journal:  Cytotechnology       Date:  2014-11-19       Impact factor: 2.058

Review 4.  Modifications of natural peptides for nanoparticle and drug design.

Authors:  Andrew P Jallouk; Rohun U Palekar; Hua Pan; Paul H Schlesinger; Samuel A Wickline
Journal:  Adv Protein Chem Struct Biol       Date:  2015-03-12       Impact factor: 3.507

5.  The UniProtKB/Swiss-Prot Tox-Prot program: A central hub of integrated venom protein data.

Authors:  Florence Jungo; Lydie Bougueleret; Ioannis Xenarios; Sylvain Poux
Journal:  Toxicon       Date:  2012-03-23       Impact factor: 3.033

Review 6.  Therapeutic potential of snake venom in cancer therapy: current perspectives.

Authors:  Vivek Kumar Vyas; Keyur Brahmbhatt; Hardik Bhatt; Utsav Parmar
Journal:  Asian Pac J Trop Biomed       Date:  2013-02

Review 7.  Why do we study animal toxins?

Authors:  Yun Zhang
Journal:  Dongwuxue Yanjiu       Date:  2015-07-18

8.  Amelioration of an undesired action of deguelin.

Authors:  Julie A Vrana; Nathan Boggs; Holly N Currie; Jonathan Boyd
Journal:  Toxicon       Date:  2013-08-07       Impact factor: 3.033

Review 9.  Neuropeptide signalling systems - An underexplored target for venom drug discovery.

Authors:  Helen C Mendel; Quentin Kaas; Markus Muttenthaler
Journal:  Biochem Pharmacol       Date:  2020-06-30       Impact factor: 5.858

10.  The bite of the honeybee: 2-heptanone secreted from honeybee mandibles during a bite acts as a local anaesthetic in insects and mammals.

Authors:  Alexandros Papachristoforou; Alexia Kagiava; Chrisovalantis Papaefthimiou; Aikaterini Termentzi; Nikolas Fokialakis; Alexios-Leandros Skaltsounis; Max Watkins; Gérard Arnold; George Theophilidis
Journal:  PLoS One       Date:  2012-10-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.